Premium
C‐peptide concentration, mortality and vascular complications in people with Type 2 diabetes. The Skaraborg Diabetes Register
Author(s) -
Pikkemaat M.,
Melander O.,
Mölstad S.,
Garberg G.,
Boström K. B.
Publication year - 2015
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.12608
Subject(s) - medicine , quartile , diabetes mellitus , diabetic retinopathy , confounding , type 2 diabetes , incidence (geometry) , retinopathy , c peptide , proportional hazards model , endocrinology , confidence interval , physics , optics
Aim To study the prognosis of patients with newly diagnosed Type 2 diabetes in primary care in relation to their baseline C‐peptide concentration. Methods C‐peptide concentrations were determined in 399 patients aged < 65 years with newly diagnosed Type 2 diabetes using the Skaraborg Diabetes Register, Sweden. Data on cardiovascular complications and death were extracted from national registers and a local study of retinopathy. Statistical analyses were performed using Cox regression. Results An analysis of C‐peptide concentrations in quartiles, after adjusting for confounders, showed that patients in the highest quartile had a 2.75‐fold higher risk of death from all causes compared with those in the lowest quartile ( CI 1.17–6.47). By contrast, C‐peptide concentration was not associated with the incidence of cardiovascular events or the development of retinopathy. Conclusions Measurement of C‐peptide concentration at diagnosis could help identify patients who are at high risk and who presumably would benefit from more intensive treatment.